Ask me later
Ask me later
How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Thanks again for rating us!
Hansa Biopharma Q2; Idefirix sales progress and secured funding to end 2024
Research Note
2022-07-19
10:00
Hansa Biopharma (Hansa) delivers another quarter with improved Idefirix European sales. The positive Q1 surprise is almost matched in Q2, and sales seem to be above both consensus and our expectations. Hansa has also secured non-equity dilutive funding to 2024 with a secured debt arrangement with US NovaQuest Capital Management. We expect a distinct positive reaction compared with the regional equity market.
JU
Johan Unnerus
Disclosures and disclaimers